Prognostic Impact of Effusion in Multiple Body Cavities After Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Int J Hematol

Specialty Hematology

Date 2025 Mar 3

PMID 40032737

Authors

Yasutaka Masuda

Akira Honda

Takashi Oyama

Yosuke Masamoto

Mineo Kurokawa

Affiliations

Soon will be listed here.

Abstract

Fluid retention presenting as effusions in body cavities is sometimes encountered following allogeneic stem cell transplantation (allo-HSCT). It is unclear whether cavity effusions at independent sites may serve as cumulative correlates of fluid overload and whether a higher number of effusion sites are associated with a worse prognosis. Here, we comprehensively reviewed pleural, peritoneal, and pericardial effusions in 178 first allo-HSCT recipients retrospectively. A total of 123 (69.1%) patients developed effusions in any cavity. New pleural, peritoneal, and pericardial effusions were found after allo-HSCT in 106, 88, and 53 patients, at a median of 38.0 (range, 2-2950), 22.5 (range, 2-1324), and 40 (range, 2-945) days, respectively. The cumulative incidence at day 100 was 41.0%, 40.4%, and 20.8%, respectively. Of the 92 patients who presented with effusions by day 100, 28 patients presented with effusion in a single cavity, 39 in two cavities, and 25 in all three cavities. The 2-year overall survival rates of patients with effusions in zero, one, two, and three cavities by day 100 were 86.1%, 60.0%, 59.6%, and 18.8%, respectively, showing an additive adverse association with outcome. Prospective studies to further characterize fluid dynamics following allo-HSCT are warranted.

References

Gooley T, Chien J, Pergam S, Hingorani S, Sorror M, Boeckh M . Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22):2091-101. PMC: 3017343. DOI: 10.1056/NEJMoa1004383. View

McDonald G, Sandmaier B, Mielcarek M, Sorror M, Pergam S, Cheng G . Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. Ann Intern Med. 2020; 172(4):229-239. PMC: 7847247. DOI: 10.7326/M19-2936. View

Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S . How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020; 4(24):6283-6290. PMC: 7756984. DOI: 10.1182/bloodadvances.2020003418. View

Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D . Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2016; 91(9):E341-7. PMC: 6852667. DOI: 10.1002/ajh.24435. View

Kubo H, Imataki O, Fukumoto T, Oku M, Ishida T, Kubo Y . Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021; 27(11):949.e1-949.e8. DOI: 10.1016/j.jtct.2021.07.024. View

Kubo H, Imataki O, Fukumoto T, Kawanaka Y, Ishida T, Kubo Y . Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023; 13(1):13005. PMC: 10415345. DOI: 10.1038/s41598-023-39604-6. View

Liu Y, Chien S, Fan N, Hu M, Gau J, Liu C . Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2015; 169(5):737-45. DOI: 10.1111/bjh.13357. View

Chen X, Zou Q, Yin J, Wang C, Xu J, Wei J . Pericardial effusion post transplantation predicts inferior overall survival following allo-hematopoietic stem cell transplant. Bone Marrow Transplant. 2015; 51(2):303-6. DOI: 10.1038/bmt.2015.227. View

Moy M, Levsky J, Berko N, Godelman A, Jain V, Haramati L . A new, simple method for estimating pleural effusion size on CT scans. Chest. 2013; 143(4):1054-1059. PMC: 3616681. DOI: 10.1378/chest.12-1292. View

10.

Armand P, Kim H, Logan B, Wang Z, Alyea E, Kalaycio M . Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-71. PMC: 4047501. DOI: 10.1182/blood-2014-01-552984. View

11.

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V . Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-33. PMC: 2861656. DOI: 10.1016/j.bbmt.2009.07.004. View

12.

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M . Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15(3):367-9. PMC: 3110087. DOI: 10.1016/j.bbmt.2008.12.497. View

13.

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

14.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

15.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

16.

Schoemans H, Lee S, Ferrara J, Wolff D, Levine J, Schultz K . EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018; 53(11):1401-1415. PMC: 6786777. DOI: 10.1038/s41409-018-0204-7. View

17.

Ho V, Cutler C, Carter S, Martin P, Adams R, Horowitz M . Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11(8):571-5. DOI: 10.1016/j.bbmt.2005.06.001. View

18.

Ruutu T, Barosi G, Benjamin R, Clark R, George J, Gratwohl A . Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007; 92(1):95-100. DOI: 10.3324/haematol.10699. View

19.

Jones R, Lee K, Beschorner W, Vogel V, Grochow L, Braine H . Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987; 44(6):778-83. DOI: 10.1097/00007890-198712000-00011. View

20.

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar A, Aljurf M . Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 51(7):906-12. PMC: 4935979. DOI: 10.1038/bmt.2016.130. View